SARS-CoV-2-IN-13

Research use only, not for human use.

SARS-CoV-2-IN-13 (compound 5) is an analogue of niclosamide, displaying greater stability in human plasma and liver S9 enzymes assay.

SARS-CoV-2-IN-13 (compound 5) is a potent inhibitor of SARS-CoV-2 with an IC50 of 0.057 μM. SARS-CoV-2-IN-13 is a niclosamide analogue. SARS-CoV-2-IN-13 contains higher stability in human plasma and liver S9 enzymes assay than niclosamide, which can improve bioavailability and half-life when administered orally.

——

——

——

Others

Other Targets

SARS-CoV

——

——

56961-10-5

327.12

C13H8Cl2N2O4

>98% (HPLC)

In Vitro:?DMSO : ≥ 125 mg/mL (382.12 mM)

Oc1ccc(Cl)cc1C(=O)Nc1ccc(c(Cl)c1)[N+]([O-])=O

——

(-20℃)

With Ice Pack

≥ 2 years